Efficient gene transfer of VSV-G pseudotyped retroviral vector to human brain tumor

Gene Therapy
H LeeJ H Kim

Abstract

A retroviral vector constructed from the murine leukemia virus (MLV) can only express transgenes in cells undergoing mitosis, indicating its suitability as a delivery vehicle for cancer gene therapy. However, the transduction efficiency (TE) of retroviruses embedding endogenous envelope proteins in human cancer cells was found to be unsatisfactory. Recently, several research groups have demonstrated the feasibility of a retroviral vector pseudotyped with a vesicular stomatitis virus G (VSV-G) protein. In this study, the potential of VSV-G pseudotyped MLV-based retrovirus was examined as a delivery vehicle in a variety of human cancer cells including brain tumor cells in vitro and in vivo. The transduction efficiency of the 293T/G/GP/LacZ retrovirus in cell culture was superior in most cancer cells, particularly in brain tumor cells, compared with that of other retroviruses, such as PA317- or PG13-derived. The relative growth rate and phosphatidylserine expression level on the plasma membrane of target cells mainly influenced the transduction efficiency of VSV-G pseudotyped retrovirus, which suggested that both the relative growth rate and phosphatidylserine expression level were major determinants of TE. Furthermore, 293T/G/GP/...Continue Reading

References

Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M Gossen, H Bujard
May 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J E FinchamJ A Strauss
Mar 1, 1995·Nature Medicine·T Friedmann, J K Yee
Aug 11, 1995·The Journal of Biological Chemistry·J ZabnerM J Welsh
Aug 1, 1995·Nature Genetics·R K HurfordR I Tepper
Jan 1, 1995·British Medical Bulletin·R G Vile, S J Russell
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·J K YeeT Friedmann
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·D S OryR C Mulligan
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·A D Miller
Feb 21, 1998·Trends in Biotechnology·P D RobbinsS C Ghivizzani
Dec 23, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M Sasaki, K H Plate

❮ Previous
Next ❯

Citations

Nov 22, 2005·Oncogene·J Michael MathisDavid T Curiel
Oct 18, 2013·Archives of Virology·Irena VoráčkováTomáš Ruml
May 1, 2007·Regenerative Medicine·Marinela Mendez-PertuzYuti Chernajovsky
Nov 26, 2010·The Journal of Gene Medicine·Xia Zhang, Monica J Roth
Apr 18, 2018·The Korean Journal of Thoracic and Cardiovascular Surgery·Yong Ho Jeong, Tae-Jin Yun
Oct 9, 2019·Circulation Research·Sara McArdleKlaus Ley
Mar 26, 2003·The Journal of General Virology·John A G BriggsStephen D Fuller

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.